S&P 5005,963+0.54%
NASDAQ21,443+0.87%
DOW43,892+0.31%
DAX23,888+0.44%
FTSE 1008,721-0.12%
EUR/USD1.1465+0.07%
GBP/USD1.3220+0.14%
USD/JPY161.31-0.03%
Gold3,241+0.22%
WTI Oil76.40+0.81%
Bitcoin103,241+1.43%
10Y UST4.47%-9bp
S&P 5005,963+0.54%
NASDAQ21,443+0.87%
DOW43,892+0.31%
DAX23,888+0.44%
FTSE 1008,721-0.12%
EUR/USD1.1465+0.07%
GBP/USD1.3220+0.14%
USD/JPY161.31-0.03%
Gold3,241+0.22%
WTI Oil76.40+0.81%
Bitcoin103,241+1.43%
10Y UST4.47%-9bp
MarketsFN
Home/Hedge Funds/Baker Bros Advisors/Q2 2024

Baker Bros Advisors

Period: Q2 2024 Β· Filed: 2024-08-14
View on SEC EDGAR β†—
AUM
$7.83B
Total portfolio value
Positions
95
Reported securities
Top Holding
INCY
23.8% $1.86B
QoQ Changes
+8 / -8
new Β· exited
⚠️13F Filing Disclosure

AUM figures shown are calculated by summing the reported market value of all positions in SEC 13F-HR filings β€” not the fund's actual assets under management.

  • Excludes cash, bonds, private equity, short positions, and foreign-listed stocks not required to be reported.
  • For PUT and CALL options, the reported Value is the notional value of the underlying shares β€” not the option premium paid. This significantly overstates the actual capital at risk.
  • Actual fund AUM is typically higher and includes strategies, instruments, and positions that never appear in a 13F.
  • 13F filings cover institutional managers with β‰₯$100M in 13F securities. Positions reflect end-of-quarter holdings, disclosed up to 45 days after the period ends.

Data sourced from SEC EDGAR. This tracker is for informational purposes only and does not constitute investment advice.

Portfolio Holdings

Top 30 positions

⚠️ Performance % calculated from filing date ( 2024-08-14) shown is the underlying stock price movement β€” not the derivative's P&L.
TickerIssuerNotionalPort %@ FilingNow (EOD)Since FilingAllocation
INCYIncyte Corporation$1.86B23.81%$60.87$116.86+92.0%
23.8%
ONCBeiGene, Ltd.$1.51B19.27%$144.89$297.65+105.4%
19.3%
ACADACADIA Pharmaceuticals Inc.$696.8M8.90%$16.04$25.97+61.9%
8.9%
MDGLMadrigal Pharmaceuticals, Inc.$553.2M7.07%$279.31$528.10+89.1%
7.1%
RVMDRevolution Medicines, Inc.$293.8M3.75%$38.81$189.24+387.6%
3.8%
RYTMRhythm Pharmaceuticals, Inc.$262.7M3.36%$42.67$114.17+167.6%
3.4%
INSMInsmed Incorporated$239.6M3.06%$66.34$111.60+68.2%
3.1%
BCYCBicycle Therapeutics plc$190.3M2.43%$20.29$4.35-78.6%
2.4%
SMMTSummit Therapeutics Inc.$181.1M2.31%$8.14$15.42+89.4%
2.3%
KYMRKymera Therapeutics, Inc.$179.0M2.29%$30.95$113.51+266.8%
2.3%
EWTXEdgewise Therapeutics, Inc.$105.2M1.34%$19.38$39.56+104.1%
1.3%
ALKSAlkermes plc$100.8M1.29%$24.39$54.58+123.8%
1.3%
Insmed Incorporated$90.4M1.16%β€”β€”
1.2%
REPLReplimune Group, Inc.$90.4M1.16%$9.36$11.58+23.7%
1.2%
DNLIDenali Therapeutics Inc.$86.7M1.11%$22.01$25.83+17.4%
1.1%
ABCLAbCellera Biologics Inc.$81.5M1.04%$2.78$8.11+191.7%
1.0%
NRIXNurix Therapeutics, Inc.$81.0M1.04%$20.91$23.97+14.6%
1.0%
IMTXImmatics N.V.$74.9M0.96%$12.00$9.95-17.1%
1.0%
TRDAEntrada Therapeutics, Inc.$69.3M0.89%$14.32$7.72-46.1%
0.9%
RAREUltragenyx Pharmaceutical Inc.$60.3M0.77%$41.12$33.47-18.6%
0.8%
STOKStoke Therapeutics, Inc.$59.0M0.75%$13.87$32.70+135.8%
0.8%
Insmed Incorporated$56.2M0.72%β€”β€”
0.7%
KNSAKiniksa Pharmaceuticals International, plc$52.6M0.67%$18.00$64.53+258.5%
0.7%
IMCRImmunocore Holdings plc$51.4M0.66%$36.43$32.50-10.8%
0.7%
ARGXargenx SE$48.1M0.61%$434.22$939.68+116.4%
0.6%
KODKodiak Sciences Inc.$40.7M0.52%$2.37$38.54+1526.2%
0.5%
XENEXenon Pharmaceuticals Inc.$38.7M0.50%$37.69$60.96+61.7%
0.5%
PRLDPrelude Therapeutics Inc.$38.6M0.49%$3.77$4.91+30.2%
0.5%
IDYAIDEAYA Biosciences, Inc.$37.3M0.48%$35.92$37.65+4.8%
0.5%
CERSCerus Corporation$34.3M0.44%$1.72$3.16+83.7%
0.4%

Quarter-on-Quarter Activity

Q2 2024 vs. Q1 2024

New Positions (8)

TickerIssuerNotionalSince Filing
SMMTSummit Therapeutics Inc.$181.1M+89.4%
ALKSAlkermes plc$100.8M+123.8%
Insmed Incorporated$90.4M
Insmed Incorporated$56.2M
KNSAKiniksa Pharmaceuticals International, plc$52.6M+258.5%
ALMSAlumis Inc.$20.8M
MRUSMerus N.V.$17.8M
DBVTDBV Technologies S.A.$5.8M

Exited Positions (8)

TickerIssuerNotionalSince Filing
KNSAKiniksa Pharmaceuticals, Ltd.$55.4M+258.5%
DBVTDBV Technologies S.A.$10.9M
HOOKHOOKIPA Pharma Inc.$5.8M
ALPNAlpine Immune Sciences, Inc.$3.2M
FDMT4D Molecular Therapeutics, Inc.$3.2M
MURAMural Oncology plc$1.1M
CABACabaletta Bio, Inc.$0.2M
CATXXXXXPerspective Therapeutics, Inc.$0.2M

Increased (8)

TickerIssuerNotionalShares Ξ”Since Filing
INSMInsmed Incorporated$230.3M+942.6%+68.2%
KALAKALA BIO, Inc.$4.2M+234.3%
GBIOGeneration Bio Co.$1.9M+225.1%
TARAProtara Therapeutics, Inc.$0.3M+168.9%
DYNDyne Therapeutics, Inc.$15.6M+135.8%
BCYCBicycle Therapeutics plc$67.2M+90.2%-78.6%
FATEFate Therapeutics, Inc.$-3.5M+64.9%
NMRANeumora Therapeutics, Inc.$1.4M+63.2%

Trimmed (8)

TickerIssuerNotionalShares Ξ”Since Filing
BCRXBioCryst Pharmaceuticals, Inc.$-51.0M-99.3%
ADAPYAdaptimmune Therapeutics plc$-14.8M-78.3%
AVTEAerovate Therapeutics, Inc.$-48.6M-62.6%
ROIVRoivant Sciences Ltd.$-48.6M-62.3%
AKROAkero Therapeutics, Inc.$-42.8M-59.6%
SAGESage Therapeutics, Inc.$-5.8M-58.0%
CERECerevel Therapeutics Holdings, Inc.$-39.7M-57.3%
ARGXargenx SE$-11.4M-26.0%+116.4%
← Back to Hedge Funds